Just Other Articles

An investor buys a share of stock by resorting to various approaches that validate his investment by reaping rich profits. Before investing, however, it is necessary for a

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

value investor to study the financials of a business, so that the stock he buys at the company’s intrinsic value promises a greater return at its liquidation value (the v

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

lue of a company if all its assets were sold). A typical investor would buy growth stocks that have an upward trend, and seem likely to keep growing for a long time. Where

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

s, a technical investor (also known as a Quant) makes decisions based upon the psychology of the market and related factors, which involve much higher risk but may prove t

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

o be more profitable, or, can conversely result in much greater losses. The fundamental analysis of any business can depend on various factors: efficient market theory, va

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ue and growth, growth at a reasonable price and the quality of the business.

1. Efficient market theory pertains to stocks being always correctly priced, as all the requi

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

ite information is available on the current price.
2. The stock market sets up the price.
3. Analysts decide upon the value of a company based on the potential f

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

or its growth.
4. Price and value may not be equal, due to certain irrationalities governing the market.

Value investors need to rely on certain stringent rules gove

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ning the nature of the stock which adhere to the following criteria:

1. Earnings: company earnings are profits after taxes and interests.
2. Earnings per share (EPS)

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

the amount of recorded income (on per share basis) available to the company to pay dividends to stockholders, or to reinvest in itself.
3. Price/Earnings Ratios (P/E

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

ratio (having a justified upper limit): If the company's stock is trading at $80 and its EPS is $8 per share, it has a multiple, or P/E of 10. This means that investors c

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ould expect a 10% cash flow return:
$8/$80 = 1/10 = 1/(PE) = 0.10 = 10%
If it's making $4 per share, it has a multiple of 20 (20 times $4 equals $80). In this c

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

se, an investor might receive a 5% return (in the same conditions);
$4/$80 = 1/20 = 1/(P/E) = 0.05 = 5%
However, a low P/E is not an untainted value indicator.<

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

r> 4. Price/Sales Ratio (PSR): is the same as a P/E ratio, except that the stocks are divided by sales per share instead of earnings per share.
5. Debt Ratio: percen

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

tage of debt a company has relative to the shareholder equity.
6. Dividend yields above a certain absolute limit.
7. Book value ratio: comparison of the market p

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ice against the book value of the stock per share.
8. Market capitalization value: Complete total value of a company’s outstanding shares (Market price per share ? To

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

al number of shares outstanding).
9. Equity Returns - ROE: Net income after taxes divided by owner’s equity.
10. Beta: comparison of volatility of the stock to t

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

hat of the market.
11. Institutional ownership: percentage of a firm’s outstanding shares owned by certain institutions: insurance companies, mutual funds etc.

Learn

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ng to analyze one’s stocks and thus reaping the desirable profit is in fact a continuous process, as no amount of market efficient theories can ever predict a flawless fin

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ncial return system. Even though one invests judiciously by studying the market, the over-valuation or under-valuation of stocks can often be determined by market emotions

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justotherarticles.org.ua/article/89875/justotherarticles-Analyze-Your-Stocks-And-Double-Your-Profit.html">Analyze Your Stocks And Double Your Profit</a>

BB link (for phorums):
[url=http://www.justotherarticles.org.ua/article/89875/justotherarticles-Analyze-Your-Stocks-And-Double-Your-Profit.html]Analyze Your Stocks And Double Your Profit[/url]

Initial public offerings (IPOs) offer companies a number of benefits, but there are some drawbacks. This article reviews factors that any business thinking about going public should consider.

What if there were no sales people? What if no one ever tried to sell you anything? Would you have a better life? Would it be better for our country? What about the economy? What about jobs? How about; the service, retail and manufacturing industry, would they do better or would all these things do worse?

Principle #4: Why would somebody want your product, solution, or opportunity? Find out why here now!

Tags

Links

Just Other Articles - Analyze Your Stocks And Double Your Profit

Related Articles: